ADAMTS Inhibitor Peptides Explained
Imagine your joints have a protective cushion called cartilage, and inside that cushion sits a molecule called aggrecan that acts like a shock absorber. Over time, especially as you age or stress your joints, your body produces enzymes called ADAMTS that essentially chew up and destroy this aggrecan. Once it's gone, your cartilage loses its cushioning ability and starts to break down—this is osteoarthritis.
ADAMTS inhibitor peptides are synthetic molecules designed to stop this damage before it happens. Think of them as bouncers standing at the entrance to aggrecan, preventing those destructive enzymes from getting close enough to tear it apart.
Here's how they work: these peptides are shaped to fit perfectly into the active site of ADAMTS enzymes—basically blocking the enzyme's "mouth" so it can't latch onto aggrecan and destroy it. By keeping aggrecan intact in your cartilage, your joints maintain their natural cushioning and can resist compression better. The result is that cartilage degradation slows down or stops altogether.
Right now researchers are testing these peptides in animal models and early human trials, and the results look promising for eventually slowing or preventing osteoarthritis progression.
Dosage Information
Typical Dose
Research compounds — no established human dosing
Frequency
N/A
Administration
Research compounds
Half-Life
varies hours
estimatedNotes
ADAMTS inhibition is an active target for OA drug development. No approved compounds yet. This entry documents the research significance of this approach to cartilage protection.
Why this matters
Research compounds; half-life depends on specific inhibitor formulation.
Where does ADAMTS Inhibitor Peptides sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.11
Potential Side Effects
ADAMTS Inhibitor Peptides discussions
Quick Facts
- Administration
- Research compounds
- Typical Dose
- Research compounds — no established human dosing
- Frequency
- N/A
- References
- 0 curated + 3 from PubMed
- Evidence Score
- 0.1 / 100
Frequently Asked Questions about ADAMTS Inhibitor Peptides
What is ADAMTS Inhibitor Peptides?
ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) inhibitor peptides are synthetic compounds targeting ADAMTS-4 and ADAMTS-5 — the primary enzymes responsible for aggrecan degradation in osteoarthritic cartilage. Aggrecan is the major proteoglycan in cartilage providing compressive resistance and ADAMTS-mediated aggrecan loss is an early and critical event in OA pathology. Peptide inhibitors of ADAMTS represent one of the most mechanistically targeted approaches to preventing cartilage degradation and are in early-stage research development.
How does ADAMTS Inhibitor Peptides work?
ADAMTS-4 and ADAMTS-5 (aggrecanases) cleave aggrecan at specific sites within the interglobular domain releasing the glycosaminoglycan-bearing regions from the cartilage matrix. This aggrecan shedding is an early event in OA preceding visible cartilage fibrillation and represents a targetable disease mechanism. Peptide inhibitors of ADAMTS typically contain sequences that mimic the aggrecan cleavage site or the ADAMTS substrate binding domain occupying the active site and blocking aggrecan degradation. By preserving aggrecan content in cartilage these inhibitors maintain the tissue's compressive resilience and may prevent or slow the structural damage of OA. Several small molecule and peptide ADAMTS inhibitors have shown efficacy in animal OA models and are in early clinical development.
What is the recommended dosage for ADAMTS Inhibitor Peptides?
The typical dose is Research compounds — no established human dosing. N/A. Administration: Research compounds. ADAMTS inhibition is an active target for OA drug development. No approved compounds yet. This entry documents the research significance of this approach to cartilage protection.
What are the side effects of ADAMTS Inhibitor Peptides?
Research compounds — limited human safety data. ADAMTS enzymes have roles beyond cartilage — off-target effects possible
Questions reflect common community inquiries. This is not medical advice.